
News|Videos|May 25, 2023
Changing the Paradigms of How We Think About Depression
Author(s)Greg Mattingly, MD
Check out this review of the 2023 APA Annual Meeting presentation on the efficacy and safety of repeat treatment courses using novel medicine, zuranolone.
Advertisement
CONFERENCE REPORTER
Greg Mattingly, MD, shares a review of the 2023 APA Annual Meeting presentation that covered long term results of the year long study on zuranolone in major depressive disorder.
Dr Mattingly is an associate clinical professor at Washington University School of Medicine, and is a physician and principal investigator in clinical trials for Midwest Research Group.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Approves ProlivRX: First Prescription, Physician-Directed, At-Home Brain Neuromodulation Therapy for MDD
2
What Makes It So Special? A Review of the Mechanisms of Action of Lamotrigine, Carbamazepine, and Valproic Acid and How They Differ From Other Antiepileptics
3
Anticholinergic Burden and Its Effect on Cognition in Psychosis
4
Progress Report: Second Interim Safety Review of Phase 3 Trial of LPCN 1154 in Postpartum Depression
5

















